Evidence map›Paper›PMID 28627960›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2018

Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma.

Nina Obad, Heidi Espedal, Radovan Jirik, Per Oystein Sakariassen, Cecilie Brekke Rygh, Morten Lund-Johansen, Torfinn Taxt, Simone P Niclou, Rolf Bjerkvig, Olivier Keunen

Open access · hybridAbstract read
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Nina Obad1 Department of Biomedecine, University of Bergen, Bergen, Norway.
Heidi Espedal1 Department of Biomedecine, University of Bergen, Bergen, Norway.
Radovan Jirik4 Institute of Scientific Instruments of the Czech Academy of Sciences, Brno, Czech Republic.
Per Oystein Sakariassen1 Department of Biomedecine, University of Bergen, Bergen, Norway.
Cecilie Brekke Rygh1 Department of Biomedecine, University of Bergen, Bergen, Norway.
Morten Lund-Johansen2 Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway.
Torfinn Taxt1 Department of Biomedecine, University of Bergen, Bergen, Norway.
Simone P Niclou3 KG Jebsen Brain Tumor research Center, University of Bergen, Bergen, Norway.
Rolf Bjerkvig1 Department of Biomedecine, University of Bergen, Bergen, Norway.
Olivier Keunen7 Norlux Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.
University of Bergen · NOLuxembourg Institute of Health · LUCzech Academy of Sciences, Institute of Scientific Instruments · CZHaukeland University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neo-angiogenesis represents an important factor for the delivery of oxygen and nutrients to a growing tumour, and is considered to be one of the main pathodiagnostic features of glioblastomas (GBM). Anti-angiogenic therapy by vascular endothelial growth factor (VEGF) blocking agents has been shown to lead to morphological vascular normalisation resulting in a reduction of contrast enhancement as seen by magnetic resonance imaging (MRI). Yet the functional consequences of this normalisation and its potential for improved delivery of cytotoxic agents to the tumour are not known. The presented study aimed at determining the early physiologic changes following bevacizumab treatment. A time series of perfusion MRI and hypoxia positron emission tomography (PET) scans were acquired during the first week of treatment, in two human GBM xenograft models treated with either high or low doses of bevacizumab. We show that vascular morphology was normalised over the time period investigated, but vascular function was not improved, resulting in poor tumoural blood flow and increased hypoxia.

Indexed as

Angiogenesis InhibitorsAnimalsBevacizumabBrain NeoplasmsFemaleGlioblastomaHumansMaleMice, NudeNeovascularization, PathologicXenograft Model Antitumor AssaysAngiogenesis InhibitorsBevacizumabAngiogenesisbevacizumabglioblastomahypoxiaperfusionVEGF

Identifiers

PMID28627960
PMCPMC6168744
OpenAlexW2685274935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.